Etoposide: adverse event reports filed with FDA

62,291

reports as suspect product

0.3% of all reports · about 2,769 a year

4,749

reports, 12 months to June 2026

5,129 in the 12 months before

97.9%

marked serious by the reporter

96.8% across the class

23.6%

record death among outcomes, as reported

14,729 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Etoposide reports recording the termmedian drug in topoisomerase inhibitor

1. Febrile neutropeniafever with low white blood cells11.6%7,217
2. Off label useused for a purpose or in a way not on the label11.4%7,093
3. Neutropenialow neutrophils, a type of white blood cell7.4%4,606
4. Disease progressionthe disease advanced6.4%4,008
5. Drug ineffectivethe medicine did not work as expected6.3%3,932
6. Thrombocytopenialow platelets6%3,738
7. Anaemialow red blood cells4.8%2,993
8. Pyrexiafever4.8%2,991
9. Sepsisa severe body-wide response to infection4.5%2,779
10. Product use in unapproved indicationused for a purpose not on the label4.3%2,693
11. Pancytopenialow counts of all blood cells4.1%2,573
12. Nauseafeeling sick3.6%2,247
13. Pneumonialung infection3.5%2,178
14. Mucosal inflammation3.3%2,057
15. Diarrhoealoose or frequent stools3.2%2,006
16. Vomitingbeing sick3.2%1,964
17. Deaththe patient died; cause not stated by this term3.1%1,955
18. Infectionan infection, type not specified2.9%1,822
19. Myelosuppression2.8%1,746
20. Malignant neoplasm progression2.8%1,719
21. Septic shockshock arising from infection2.3%1,460
22. Acute myeloid leukaemia2.2%1,380
23. Dyspnoeashortness of breath2.2%1,362
24. Fatiguetiredness2.1%1,310
25. Bone marrow failure2%1,216
26. Leukopenialow white blood cells1.9%1,199
27. Platelet count decreasedlow platelet count1.9%1,173
28. Respiratory failurethe lungs could not supply enough oxygen1.8%1,149
29. Myelodysplastic syndrome1.8%1,133
30. Acute kidney injurysudden loss of kidney function1.7%1,085

Top 30 of 3,529 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 12 drugs in the topoisomerase inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 86,440 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 26.7% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 62,291 reports.

Drugs most often listed in the same reports

Other products listed in reports where Etoposide is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the topoisomerase inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Etoposide as a suspect or interacting product; reports listing it only as a concomitant medication (12,281) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.